Leukemia Clinical Trials in Denver

Showing 661-680 of 1,554 trials

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

NCT02009449

This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with chemotherapy or immunotherapy.

MelanomaProstate CancerOvarian Cancer+6 more

Eli Lilly and Company353 participantsStarted Nov 2013

Los Angeles, California, United States • San Francisco, California, United States • Denver, Colorado, United States +7 more locations

TERMINATEDPhase 1/2< 1 mile

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

NCT04358458

The drug that will be investigated in the study is an antibody, GEN3009. Since this is the first study of GEN3009 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN3009 dose to be tested in a larger group of patients and assess preliminary clinical activity of GEN3009. GEN3009 will be studied in a broad group of cancer patients, having different kinds of lymphomas. All patients will get GEN3009 either as a single treatment (monotherapy) or in combination with another antibody-candidate for treatment of cancer in the blood. The study consists of two parts: Part 1 tests increasing doses of GEN3009 ("escalation"), followed by Part 2 which tests the recommended GEN3009 dose from Part 1 ("expansion").

Diffuse Large B-cell LymphomaFollicular LymphomaMarginal Zone Lymphoma+5 more

Genmab46 participantsStarted Mar 2020

Denver, Colorado, United States • Cleveland, Ohio, United States • Columbus, Ohio, United States +14 more locations

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Leukemia Trials in Other Cities

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Milademetan in Advanced/Metastatic Solid Tumors

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

Other Conditions in Denver